Gattinoni et al. have shown that early effector CD8 T cells (similar to MPECs, with higher levels of CD127) are better able to reject a large, established B16 murine melanoma tumor than intermediate or full effector CD8 T cells (similar to SLECs, with higher levels of KLRG1) [26]. The gene discussed is CD8A; the disease is melanoma.